MGX — Metagenomi Therapeutics Share Price
0.000.00%
Last trade - 00:00- $57.82m
- -$126.29m
- $52.30m
- 30
- 57
- 56
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.32 | ||
| Price to Tang. Book | 0.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.87 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -42.26% | ||
| Return on Equity | -40.87% | ||
| Operating Margin | -298.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.24 | 17.2 | 44.76 | 52.3 | 27.97 | 21.99 | 499.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. It is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. It focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- September 16th, 2016
- Public Since
- February 9th, 2024
- No. of Shareholders
- 221
- No. of Employees
- 124
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 37,546,751
- Address
- 5959 Horton St, Floor 7, EMERYVILLE, 94608
- Web
- https://metagenomi.co/
- Phone
- +1 5108714880
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for MGX
Q1 2026 Metagenomi Therapeutics Inc Earnings Release
Metagenomi Therapeutics Inc Annual Shareholders Meeting
Similar to MGX
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Metagenomi Therapeutics share price?
As of Today at 21:01 UTC, shares in Metagenomi Therapeutics are trading at $1.54. This share price information is delayed by 15 minutes.
How has the Metagenomi Therapeutics share price performed this year?
Shares in Metagenomi Therapeutics last closed at $1.54 and the price had moved by -41.67% over the past 365 days. In terms of relative price strength the Metagenomi Therapeutics share price has underperformed the S&P500 Index by -49.29% over the past year.
What are the analyst and broker recommendations for Metagenomi Therapeutics?
The overall consensus recommendation for Metagenomi Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Metagenomi Therapeutics dividend yield?
Metagenomi Therapeutics does not currently pay a dividend.
Does Metagenomi Therapeutics pay a dividend?
Metagenomi Therapeutics does not currently pay a dividend.
When does Metagenomi Therapeutics next pay dividends?
Metagenomi Therapeutics does not currently pay a dividend.
How do I buy Metagenomi Therapeutics shares?
To buy shares in Metagenomi Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Metagenomi Therapeutics?
As of the previous close price of $1.54, shares in Metagenomi Therapeutics had a market capitalisation of $57.82m.
Where are Metagenomi Therapeutics shares listed?
Here are the trading details for Metagenomi Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MGX
What kind of share is Metagenomi Therapeutics?
Based on an overall assessment of its quality, value and momentum Metagenomi Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Metagenomi Therapeutics share price forecast for 2026?
The analyst consensus target price for shares in Metagenomi Therapeutics is $9.33. That is 505.84% above the last closing price of $1.54.
Analysts covering Metagenomi Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.36 for the next financial year.
Find out moreWhat is the trend in the Metagenomi Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Metagenomi Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -26.26%.
As of the last closing price of $1.54, shares in Metagenomi Therapeutics were trading -19.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Metagenomi Therapeutics PE Ratio?
The Metagenomi Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Metagenomi Therapeutics?
We do not have data on Metagenomi Therapeutics' directors